DOCSLIB.ORG

Effect of Cyproterone Acetate on Puberty in Rats

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Effect of Cyproterone Acetate on Puberty in Rats EFFECT OF CYPROTERONE ACETATE ON PUBERTY IN RATS H. STEINBECK and F. NEUMANN Experimental Research Pharma, Schering AG, Department of Endocrinology, 1 Berlin 651 {Received I5tk August 1970) Summary. Cyproterone acetate treatment delayed the ability of adolescent male rats to inseminate and impregnate female rats. Within 6 weeks of the cessation of treatment, full fertility was achieved. After a 9-week recovery period, the accessory sexual gland weights were still less than those of controls. From experiments on adult rats, this might have been expected because the recovery time was too short. Body weights remained below those of controls throughout the observation period. Certain advantages of antiandrogen treatment over other steroid medication in cases of male precocious puberty are suggested. INTRODUCTION Puberty has been defined as the stage of development at which the ability to reproduce sexually is achieved, i.e. when germ cells are released (Asdell, 1946; Critchlow & Bar-Sela, 1967). In male rats, it is not possible to advance this time because of the length of the spermatogenic cycle which already covers most of the period between birth and puberty. A further problem is to attempt to delay the onset of puberty without interference with later reproductive life. Paedia¬ tricians are confronted with this problem in cases of precocious puberty. Medroxyprogesterone acetate has been the main steroid used clinically in boys and girls (Kupperman & Epstein, 1962; Bierich & Nowak, 1965; Laron & Rumney, 1965; Thamdrup, 1965; van der Werff ten Bosch, 1965; Schoen, 1966), the principal objective of treatment being to prevent androgen-mediated premature epiphysial closure and resultant dwarfism. The effective principle of medroxyprogesterone acetate action is not a direct androgen antagonism but rather an inhibition of gonadotrophin release which, in turn, leads to decreased androgen secretion (see Neumann, 1969). The use of antiandrogens in the treatment of precocious puberty has, therefore, been proposed (Laron, 1968; Helge, Weber, Neumann & Hammerstein, 1969; Steinbeck, von Berswordt- Wallrabe, Elger, Hahn & Neumann, 1969) as a more specific form oftreatment. This study deals with the effects of peripubertal cyproterone acetate treat¬ ment on the reproductive performance of male rats. The influence of this treat¬ ment on bone growth has been published elsewhere (Hertel, Kramer & Neumann, 1969). 59 Downloaded from Bioscientifica.com at 10/04/2021 04:07:05AM via free access 60 H. Steinbeck and F. Neumann MATERIAL AND METHODS Thirteen male Sprague-Dawley rats were given a daily subcutaneous injection of 5-0 mg cyproterone acetate/100 g body weight from the 25th to 80th day of life. Commencing at the 40th day of life, fertility tests were performed at weekly intervals until a 100% impregnation rate was achieved in three successive tests. The body weight was also recorded every week. To evaluate insemination and impregnation rates, each male was placed overnight with two pro-oestrous females. The following morning, the females were separated from the males and checked for vaginal plugs and the presence of spermatozoa in vaginal smears. Eight days later, the females were killed and implantation sites were counted. At the end of the experiments, the males were killed and the weights of the following organs were recorded: testes, prostates, seminal vesicles, levator ani muscles, preputial glands and adrenals. A solvent-treated group of fourteen rats from the same batch served as controls for all measurements. RESULTS The spermatogenic cycle in male rats commences at 4 to 6 days of age and lasts 40 days to the completion of spermatogenesis (Clermont & Perey, 1957; Roosen-Runge, 1962). Another 13 to 14 days are required for transport of spermatozoa to the vas deferens and their final maturation to become fertile at the age of 57 to 60 days (Clegg, 1960). As can be seen from Text-fig. 1, this was the time at which puberty was reached in the control group as evaluated by insemination and impregnation rates. Within 2 weeks, all rats in this group were able to reproduce. Treatment period 100 80 - % 60 - 40- 20 - 40 47 54 61 68 75 82 89 96 103 110 117 124 131 138 25 80 Days of age Text-fig. 1. Influence of peripubertal cyproterone acetate treatment on the reproductive performance of male rats (·). O, Controls.-, Insemination;-, Impregna¬ tion. By contrast, only a very small percentage of the cyproterone-acetate-treated males inseminated females during the treatment period and none of these matings was fertile. Whereas the first rats of the control group began to copulate at the 54th day, treated rats did not copulate until the 61st day, by which time all the controls had inseminated females with a 93 % impregnation rate. Downloaded from Bioscientifica.com at 10/04/2021 04:07:05AM via free access Effect of cyproterone acetate on puberty in rats 61 The first fertile mating was seen 16 days after cessation of treatment, but it was not until 28 days that all treated rats achieved the ability to reproduce. The growth rate was significantly reduced in cyproterone-acetate-treated rats from the 28th day of treatment, and their body weights were still below those of the controls 64 days after the cessation of treatment (Text-fig. 2). Days of age Text-fig. 2. Influence of peripubertal cyproterone acetate treatment on the body weight development of male rats (·). o, Controls. Table 1 organ weights at the 144th day of life after cyproterone acetate treatment (5-0 mg/100 g b.wt) from the 25th to 80th day of life No. of Seminal Levator ani animals Adrenal Testis vesicle Prostate muscle Cyproterone acetate 13 13 + 0-78 932 ±25-53 264+19-42 119 + 9-84 48 ±1-89 Controls 14 13 + 0-61 777+16-26 407+13-72 230 + 6-71 66 + 2-17 All weights expressed in mg/100 g b.wt, means + S.D. All weight differences are statistically significant at the 99% level in the U-test of Mann & Whitney (1947). Although the testicular weights in treated animals were higher than the control weights after a 64-day recovery period, the weights of the accessory sexual glands were still considerably depressed (Table 1). There was, however, no difference in adrenal weights at the time of autopsy. Downloaded from Bioscientifica.com at 10/04/2021 04:07:05AM via free access 62 H. Steinbeck and F. Neumann DISCUSSION To our knowledge, this is the first report to show that peripubertal antiandrogen treatment does not interfere with later reproductive performance. Within 6 weeks of the cessation of treatment, fertile matings were achieved by all rats although their accessory sexual gland weights were still significantly depressed after a 2-month recovery period. Full restoration of these organs could not, however, be expected by this time because studies on adult rats with comparable cyproterone acetate doses revealed that full restoration of the accessory glands is not achieved until 12 to 15 weeks after the end of treatment (Steinbeck, Mehring & Neumann, 1971). The body growth rate decreased during treatment, presumably due to the antianabolic effect of the compound (Junkmann & Neumann, 1964; Neumann, von Berswordt-Wallrabe, Elger, Steinbeck & Hahn, 1968). Because the rate of growth only returned to normal levels about 5 weeks after the cessation of treatment and did not increase, the body weight of the treated group remained significantly smaller than that of the controls. Presumably the body weight development reflects not only the antianabolic effects but also skeletal changes since it has been shown that similar cyproterone acetate treat¬ ment delays bone maturation and alters bone growth (Hertel et al., 1969). As has been demonstrated with medroxyprogesterone acetate in humans, cyproterone acetate delays the time at which the ability to reproduce is achieved in male rats. This effect common to both compounds is achieved by completely different mechanisms. Whereas cyproterone acetate inhibits androgen effects mainly at the receptor sites, medroxyprogesterone acetate interferes with andro¬ gen synthesis by gonadotrophin inhibition. This raises some theoretical objec¬ tions against the use of medroxyprogesterone acetate. It is known that, after prolonged gonadotrophin suppression, hypothalamic regulatory centres become more and more insensitive to the suppressing agent (Hohlweg, 1956). Therefore, increasing amounts of gonadotrophins might escape central suppression and stimulate androgen synthesis unless the suppressor dose is increased. These androgens and also androgens from other sources, e.g. from the adrenals, are not counteracted and might be sufficient to exert undesirable effects. Cyproterone acetate, on the other hand, not only antagonizes androgens from all sources but also exerts some inhibitory action on the adrenals, pre¬ sumably by acth depression (Domenico & Neumann, 1967). Gonadotrophin secretion, and hence gonadal function, is not, or is only slightly, affected (Steinbeck et al, 1971). With due reservations, it might therefore be assumed that antiandrogen treatment has some advantage over mere gonadotrophin-secretion-inhibitory treatment in cases of male precocious puberty. REFERENCES Asdell, S. A. (1946) Patterns of mammalian reproduction. Comstock, Ithaca, New York. Bierich, J. R. & Nowak, A. H. (1965) Investigations on precocious puberty. Acta endocr., Copenh. Suppl. 101, 20. Clegg, E. J. (1960) The age at which male rats become fertile. J. Reprod. Fert. 1, 119. Downloaded from Bioscientifica.com at 10/04/2021 04:07:05AM via free access Effect of cyproterone acetate on puberty in rats 63 Clermont, Y. & Perey, B. (1957) Quantitative study of the cell population of the seminiferous tubules in immature rats. Am. J. Anat. 100, 241. Critchlow, V. & Bar-Sela, M. E. (1967) Control ofthe onset ofpuberty. In: Neuroendocrinology, vol. II, chap. 20, p. 101. Eds. L. Martini and W. F. Ganong. Academic Press, New York. Domenico, A. & Neumann, F. (1967) Wirkung von antiandrogen wirksamen Steroiden auf die Funktion und Morphologie der Nebennieren von Ratten. In: 12. Symp. Dtsch. Ges. für Endokrinologie, p.
Load more

Recommended publications
  • Download PDF File
    Ginekologia Polska 2019, vol. 90, no. 9, 520–526 Copyright © 2019 Via Medica ORIGINAL PAPER / GYNECologY ISSN 0017–0011 DOI: 10.5603/GP.2019.0091 Anti-androgenic therapy in young patients and its impact on intensity of hirsutism, acne, menstrual pain intensity and sexuality — a preliminary study Anna Fuchs, Aleksandra Matonog, Paulina Sieradzka, Joanna Pilarska, Aleksandra Hauzer, Iwona Czech, Agnieszka Drosdzol-Cop Department of Pregnancy Pathology, Department of Woman’s Health, School of Health Sciences in Katowice, Medical University of Silesia, Katowice, Poland ABSTRACT Objectives: Using anti-androgenic contraception is one of the methods of birth control. It also has a significant, non-con- traceptive impact on women’s body. These drugs can be used in various endocrinological disorders, because of their ability to reduce the level of male hormones. The aim of our study is to establish a correlation between taking different types of anti-androgenic drugs and intensity of hirsutism, acne, menstrual pain intensity and sexuality . Material and methods: 570 women in childbearing age that had been using oral contraception for at least three months took part in our research. We examined women and asked them about quality of life, health, direct causes and effects of that treatment, intensity of acne and menstrual pain before and after. Our research group has been divided according to the type of gestagen contained in the contraceptive pill: dienogest, cyproterone, chlormadynone and drospirenone. Ad- ditionally, the control group consisted of women taking oral contraceptives without antiandrogenic component. Results: The mean age of the studied group was 23 years ± 3.23. 225 of 570 women complained of hirsutism.
    [Show full text]
  • Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals
    Journal of Clinical Medicine Review Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals Carlotta Cocchetti 1, Jiska Ristori 1, Alessia Romani 1, Mario Maggi 2 and Alessandra Daphne Fisher 1,* 1 Andrology, Women’s Endocrinology and Gender Incongruence Unit, Florence University Hospital, 50139 Florence, Italy; [email protected] (C.C); jiska.ristori@unifi.it (J.R.); [email protected] (A.R.) 2 Department of Experimental, Clinical and Biomedical Sciences, Careggi University Hospital, 50139 Florence, Italy; [email protected]fi.it * Correspondence: fi[email protected] Received: 16 April 2020; Accepted: 18 May 2020; Published: 26 May 2020 Abstract: Introduction: To date no standardized hormonal treatment protocols for non-binary transgender individuals have been described in the literature and there is a lack of data regarding their efficacy and safety. Objectives: To suggest possible treatment strategies for non-binary transgender individuals with non-standardized requests and to emphasize the importance of a personalized clinical approach. Methods: A narrative review of pertinent literature on gender-affirming hormonal treatment in transgender persons was performed using PubMed. Results: New hormonal treatment regimens outside those reported in current guidelines should be considered for non-binary transgender individuals, in order to improve psychological well-being and quality of life. In the present review we suggested the use of hormonal and non-hormonal compounds, which—based on their mechanism of action—could be used in these cases depending on clients’ requests. Conclusion: Requests for an individualized hormonal treatment in non-binary transgender individuals represent a future challenge for professionals managing transgender health care. For each case, clinicians should balance the benefits and risks of a personalized non-standardized treatment, actively involving the person in decisions regarding hormonal treatment.
    [Show full text]
  • How to Select Pharmacologic Treatments to Manage Recidivism Risk in Sex Off Enders
    How to select pharmacologic treatments to manage recidivism risk in sex off enders Consider patient factors when choosing off -label hormonal and nonhormonal agents ® Dowden Healthex offenders Media traditionally are managed by the criminal justice system, but psychiatrists are fre- Squently called on to assess and treat these indi- CopyrightFor personalviduals. use Part only of the reason is the overlap of paraphilias (disorders of sexual preference) and sexual offending. Many sexual offenders do not meet DSM criteria for paraphilias,1 however, and individuals with paraphil- ias do not necessarily commit offenses or come into contact with the legal system. As clinicians, we may need to assess and treat a wide range of sexual issues, from persons with paraphilias who are self-referred and have no legal involvement, to recurrent sexual offenders who are at a high risk of repeat offending. Successfully managing sex offenders includes psychological and pharmacologic interven- 2009 © CORBIS / TIM PANNELL 2009 © CORBIS / tions and possibly incarceration and post-incarceration Bradley D. Booth, MD surveillance. This article focuses on pharmacologic in- Assistant professor terventions for male sexual offenders. Department of psychiatry Director of education Integrated Forensics Program University of Ottawa Reducing sexual drive Ottawa, ON, Canada Sex offending likely is the result of a complex inter- play of environment and psychological and biologic factors. The biology of sexual function provides nu- merous targets for pharmacologic intervention, in- cluding:2 • endocrine factors, such as testosterone • neurotransmitters, such as serotonin. The use of pharmacologic treatments for sex of- fenders is off-label, and evidence is limited. In general, Current Psychiatry 60 October 2009 pharmacologic treatments are geared toward reducing For mass reproduction, content licensing and permissions contact Dowden Health Media.
    [Show full text]
  • Determination of 17 Hormone Residues in Milk by Ultra-High-Performance Liquid Chromatography and Triple Quadrupole Mass Spectrom
    No. LCMSMS-065E Liquid Chromatography Mass Spectrometry Determination of 17 Hormone Residues in Milk by Ultra-High-Performance Liquid Chromatography and Triple Quadrupole No. LCMSMS-65E Mass Spectrometry This application news presents a method for the determination of 17 hormone residues in milk using Shimadzu Ultra-High-Performance Liquid Chromatograph (UHPLC) LC-30A and Triple Quadrupole Mass Spectrometer LCMS- 8040. After sample pretreatment, the compounds in the milk matrix were separated using UPLC LC-30A and analyzed via Triple Quadrupole Mass Spectrometer LCMS-8040. All 17 hormones displayed good linearity within their respective concentration range, with correlation coefficient in the range of 0.9974 and 0.9999. The RSD% of retention time and peak area of 17 hormones at the low-, mid- and high- concentrations were in the range of 0.0102-0.161% and 0.563-6.55% respectively, indicating good instrument precision. Method validation was conducted and the matrix spike recovery of milk ranged between 61.00-110.9%. The limit of quantitation was 0.14-0.975 g/kg, and it meets the requirement for detection of hormones in milk. Keywords: Hormones; Milk; Solid phase extraction; Ultra performance liquid chromatograph; Triple quadrupole mass spectrometry ■ Introduction Since 2008’s melamine-tainted milk scandal, the With reference to China’s national standard GB/T adulteration of milk powder has become a major 21981-2008 "Hormone Multi-Residue Detection food safety concern. In recent years, another case of Method for Animal-derived Food - LC-MS Method", dairy product safety is suspected to cause "infant a method utilizing solid phase extraction, ultra- sexual precocity" (also known as precocious puberty) performance liquid chromatography and triple and has become another major issue challenging the quadrupole mass spectrometry was developed for dairy industry in China.
    [Show full text]
  • Referral Support Service Gynaecology
    Referral Support Service Gynaecology GY11 Heavy Menstrual Bleeding (Menorrhagia and Polymenorrhagia) Definitions Menorrhagia: Excessive menstrual blood loss which interferes with the woman’s physical, emotional, social and material quality of life and which can occur alone or in combination with other symptoms. Polymenorrhagia: Frequent heavy bleeding, with shortening of menstrual cycle (eg < K- 5/21) for more than 3 cycles. Most cases are due to Dysfunctional uterine bleeding (DUB), however, this is a diagnosis of exclusion. Exclude Red Flag Symptoms Postmenopausal Bleeding (PMB) i.e. bleeding >12 months after last period over age 55 Persistent Intermenstrual bleeding (IMB): if >45 or other risk factors for endometrial cancer (eg obesity, PCOS unopposed oestrogen, tamoxifen) Treatment failure in women aged 45 years or over Significant anaemia- Hb< 8- consider admission for transfusion/ urgent referral Suspicious USS features General Points History: Sudden change in bleeding pattern? Recent childbirth? Recent change in contraception? Family history/ onset of HMB from puberty- consider von Willebrand Disease. Examination: Consider infection (especially if under 25 or change in partner) Abdominal examination/ Pelvic examination (is there pain, is there an enlarged uterus?) Investigations: Bloods: FBC, TFTs.(check for vWF if onset of HBM from puberty) Consider USS if enlarged uterus or new change in bleeding pattern. Refer for hysteroscopy if any suspected polyps or thickened endometrium on USS. How to Reduce Sudden/New onset
    [Show full text]
  • Combined Estrogen–Progestogen Menopausal Therapy
    COMBINED ESTROGEN–PROGESTOGEN MENOPAUSAL THERAPY Combined estrogen–progestogen menopausal therapy was considered by previous IARC Working Groups in 1998 and 2005 (IARC, 1999, 2007). Since that time, new data have become available, these have been incorporated into the Monograph, and taken into consideration in the present evaluation. 1. Exposure Data 1.1.2 Progestogens (a) Chlormadinone acetate Combined estrogen–progestogen meno- Chem. Abstr. Serv. Reg. No.: 302-22-7 pausal therapy involves the co-administration Chem. Abstr. Name: 17-(Acetyloxy)-6-chlo- of an estrogen and a progestogen to peri- or ropregna-4,6-diene-3,20-dione menopausal women. The use of estrogens with IUPAC Systematic Name: 6-Chloro-17-hy- progestogens has been recommended to prevent droxypregna-4,6-diene-3,20-dione, acetate the estrogen-associated risk of endometrial Synonyms: 17α-Acetoxy-6-chloro-4,6- cancer. Evidence from the Women’s Health pregnadiene-3,20-dione; 6-chloro-Δ6-17- Initiative (WHI) of adverse effects from the use acetoxyprogesterone; 6-chloro-Δ6-[17α] of a continuous combined estrogen–progestogen acetoxyprogesterone has affected prescribing. Patterns of exposure Structural and molecular formulae, and relative are also changing rapidly as the use of hormonal molecular mass therapy declines, the indications are restricted, O CH and the duration of the therapy is reduced (IARC, 3 C 2007). CH3 CH3 O C 1.1 Identification of the agents CH3 H O 1.1.1 Estrogens HH For Estrogens, see the Monograph on O Estrogen-only Menopausal Therapy in this Cl volume. C23H29ClO4 Relative molecular mass: 404.9 249 IARC MONOGRAPHS – 100A (b) Cyproterone acetate Structural and molecular formulae, and relative Chem.
    [Show full text]
  • Long-Term Menopausal Treatment Using an Ultra-High Dosage of Tibolone in an Elderly Chinese Patient – Case Report
    Long-term menopausal treatment using an ultra-high dosage of tibolone in an elderly Chinese patient – Case report Lingyan Zhang 1, Xiangyan Ruan 1,2*, Muqing Gu 1, Alfred O. Mueck 1,2 1 Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, China; 2 Department of Women’s Health, University Women’s Hospital and Research Centre for Women’s Health, University of Tuebingen, Tuebingen D-72076, Germany) ABSTRACT This report describes the special case of a Chinese woman with severe vasomotor symptoms (VSMs), depressed mood, low energy and genitourinary syndrome of menopause, including problems of sexual dysfunction, who was treated with tibolone. The aim of the report is to highlight the value of individualizing menopausal hormone therapy (MHT) type and dosage. Since 16 years of previous treatment with various other forms of MHT had not provided satisfactory efficacy in this patient, at the age of 71 years she was prescribed tibolone, starting at the usual lowest dosage of 1.25 mg/day. We gradually had to increase the dosage of tibolone up to 7.5 mg/day, which is three-fold the recommended maximum dosage. We added three-monthly sequential dydrogesterone to reduce the risk of breakthrough bleeding and the risk of endometrial cancer. To date, we have observed no side effects and no remarkable abnormal laboratory assessments, with the exception of increased thyroid-stimulating hormone, which we monitor six-monthly. Even though the patient has been informed about potential risks, such as increased risks of stroke, breast cancer and endometrial cancer, as described in the discussion, she has now been willing to accept this ultra-high dosage for seven years, and wishes to continue with this treatment.
    [Show full text]
  • Combined Estrogen–Progestogen Menopausal Therapy
    PHARMACEUTICALS volume 100 A A review of humAn cArcinogens This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 14-21 October 2008 LYON, FRANCE - 2012 iArc monogrAphs on the evAluAtion of cArcinogenic risks to humAns COMBINED ESTROGEN–PROGESTOGEN MENOPAUSAL THERAPY Combined estrogen–progestogen menopausal therapy was considered by previous IARC Working Groups in 1998 and 2005 (IARC, 1999, 2007). Since that time, new data have become available, these have been incorporated into the Monograph, and taken into consideration in the present evaluation. 1. Exposure Data 1.1.2 Progestogens (a) Chlormadinone acetate Combined estrogen–progestogen meno- Chem. Abstr. Serv. Reg. No.: 302-22-7 pausal therapy involves the co-administration Chem. Abstr. Name: 17-(Acetyloxy)-6-chlo- of an estrogen and a progestogen to peri- or ropregna-4,6-diene-3,20-dione menopausal women. The use of estrogens with IUPAC Systematic Name: 6-Chloro-17-hy- progestogens has been recommended to prevent droxypregna-4,6-diene-3,20-dione, acetate the estrogen-associated risk of endometrial Synonyms: 17α-Acetoxy-6-chloro-4,6- cancer. Evidence from the Women’s Health pregnadiene-3,20-dione; 6-chloro-Δ6-17- Initiative (WHI) of adverse effects from the use acetoxyprogesterone; 6-chloro-Δ6-[17α] of a continuous combined estrogen–progestogen acetoxyprogesterone has affected prescribing. Patterns of exposure Structural and molecular formulae, and relative are also changing rapidly as the use of hormonal molecular mass therapy declines, the indications are restricted, O CH and the duration of the therapy is reduced (IARC, 3 C 2007).
    [Show full text]
  • Effect of Tibolone on Bone Mineral Density in Postmenopausal Women: Systematic Review and Meta-Analysis
    biology Review Effect of Tibolone on Bone Mineral Density in Postmenopausal Women: Systematic Review and Meta-Analysis Lizett Castrejón-Delgado 1, Osvaldo D. Castelán-Martínez 2 , Patricia Clark 3, Juan Garduño-Espinosa 4, Víctor Manuel Mendoza-Núñez 1 and Martha A. Sánchez-Rodríguez 1,* 1 Research Unit on Gerontology, Facultad de Estudios Superiores Zaragoza, Universidad Nacional Autónoma de México, Mexico City 09230, Mexico; [email protected] (L.C.-D.); [email protected] (V.M.M.-N.) 2 Clinical Pharmacology Laboratory, Facultad de Estudios Superiores Zaragoza, Universidad Nacional Autónoma de México, Mexico City 09230, Mexico; [email protected] 3 Clinical Epidemiology Research Unit, Hospital Infantil de México Federico Gómez, Mexico City 06720, Mexico; [email protected] 4 Research Department, Hospital Infantil de México Federico Gómez, Mexico City 06720, Mexico; [email protected] * Correspondence: [email protected]; Tel.: +52-55-5623-0700 (ext. 83210) Simple Summary: Low bone mineral density (osteoporosis) is associated with vertebral and non- vertebral fractures in postmenopausal women. Tibolone is a low-risk hormone replacement therapy alternative to estrogen therapy, effective in the treatment of menopausal symptoms and prevention of bone loss, but the evidence is controversial. This systematic review with meta-analysis summarizes Citation: Castrejón-Delgado, L.; the clinical trials of the tibolone effect on percentage change of bone mineral density in the lumbar Castelán-Martínez, O.D.; Clark, P.; spine, femoral neck, and total hip in postmenopausal women. The results show that tibolone 2.5 mg Garduño-Espinosa, J.; dose increases the percent change in bone mineral density compared with non-active controls at Mendoza-Núñez, V.M.; 24 months in lumbar spine and femoral neck, regardless of the scanner used to evaluate the bone Sánchez-Rodríguez, M.A.
    [Show full text]
  • Cyproterone Acetate and the Risk of Hepatic Toxicity CONFIDENTIAL
    Cyproterone acetate and the risk of hepatic toxicity CONFIDENTIAL Medicines Adverse Reactions Committee Meeting date 5 December 2019 Agenda item 3.2.3 Title Cyproterone acetate and the risk of hepatic toxicity Medsafe Pharmacovigilance Submitted by Paper type For advice Team Active constituent Medicines Sponsors Cyproterone Procur tablets Douglas Pharmaceuticals Limited Siterone tablets REX Medical Ltd Funding Siterone 50 mg and 100 mg are funded Previous MARC Cyproterone use as a contraceptive has been discussed previously at the meetings following meeting: − 171st Meeting — 14 September 2017 Risks of severe depression, anxiety and suicidal ideation with hormonal contraceptives . Prescriber Update There have been articles regarding the risk of VTE when cyproterone is used as a contraceptive. Schedule Prescription medicine Usage data See section 2.4 Advice sought The Committee is asked to advise whether: − The data sheets for cyproterone tablets should be updated regarding the risk of hepatic toxicity. − This topic requires further communication other than MARC’s Remarks in Prescriber Update. Medicines Adverse Reactions Committee: 5 December 2019 Page 1 of 19 Cyproterone acetate and the risk of hepatic toxicity CONFIDENTIAL Table of Contents Medicines Adverse Reactions Committee .............................................................................................. 1 1.0 PURPOSE .................................................................................................................................. 3 2.0 BACKGROUND ........................................................................................................................
    [Show full text]
  • < MOH Approved Drugs List >
    Ministry Of Health Directorate General of Medical Supplies Rep_Id : App_Drugs_List_Who.rdf < MOH Approved Drugs List > DATE : 12/08/2009 Page : 1 of 108 VED Flag <S.No> < Item Code > < I T E M D E S C ROF I P- T I O N > < U N I T > DATE : ABC Flag H/C Flag Category : DRUGS 1 Ph. System : GASTRO-INTESTINAL SYSTEM 1 Main Group : ANTACIDS 1 Sub Group : ALUMINIUM COMPOUNDS 1 03000000105 ALUMINIUM HYDROXIDE GEL, DRIED 475 MG. CAPSULE Desirable Cat_C Not H/C Item 2 Sub Group : ANTACID COMPOUND PREPARATIONS 2 02000000079 ANTACID SUSPENSION (ALUMINIUM HYDROXIDE + BOTTLE Desirable MAGNESIUM HYDROXIDE OR TRISILICATE) 100 - 200 Cat_A ML. B0TTLE. H/C Item 3 03000000173 ANTACID TABLET (ALUMINIUM HYDROXIDE + TABLET/CAP Desirable MAGNESIUM HYDROXIDE OR TRISILICATE). Cat_A H/C Item 2 Main Group : ANTISPASMODICS 1 Sub Group : ANTIMUSCARINICS 4 01000000304 HYOSCINE N BUTYLBROMIDE 20MG/ML. 1ML. AMPOULE Essantial Cat_A H/C Item 5 03000000640 HYOSCINE N BUTYL BROMIDE 10MG. TABLET/CAP Essantial Cat_A H/C Item 6 020D0000063 ANTISPASMODIC DROPS 15ML-25ML. BOTTLE Desirable Cat_C Not H/C Item 2 Sub Group : OTHER ANTISPASMODIC AND MOTILITY STIMULANT 7 03000001245 MEBEVERINE HYDROCHLORIDE 100 MG - 135 MG. TABLET/CAP Essantial Cat_B Not H/C Item Ministry Of Health Directorate General of Medical Supplies Rep_Id : App_Drugs_List_Who.rdf < MOH Approved Drugs List > DATE : 12/08/2009 Page : 2 of 108 VED Flag <S.No> < Item Code > < I T E M D E S C ROF I P- T I O N > < U N I T > DATE : ABC Flag H/C Flag Category : DRUGS 1 Ph.
    [Show full text]
  • The Realization of New Medical Alternatives to Surgery for Endometriosis
    Paradigm Shift: The Realization of New Medical Alternatives to Surgery for Endometriosis Edward M. Lichten, MD* ©2016, Edward M. Lichten, MD Journal Compilation ©2016, AARM DOI 10.14200/jrm.2016.5.0099 ABSTRACT Endometriosis is one of the most destructive benign diseases of women. It is established as developing and being present in upward of 70% of adolescents who do not experience relief of menstrual pain with use of oral contraceptives and anti- inflammatory drugs. It occurs in 8%–10% of women in the United States and is most prevalent in developed countries. Symptoms of endometriosis include disabling pain, hemorrhagic uterine bleeding, and infertility. Women with disease can expect a 12% hysterectomy rate. While present medical therapy may offer relief of many symptoms, there have been no major new directions in pharmacologic therapy since leuprolide acetate was made available in 1977. Danazol remains the only alternative to GnRH agonists with proven efficacy and reasonable side effects, according to Cochrane Reviews, yet, it is underused, and GnRH agonists are favored even when Danazol in combination seems more effective. A previously published case report on use of the combination of nandrolone and stanozolol to treat a young woman scheduled for hemicolectomy is discussed as an alternative to surgery along with the limits of standard therapy. This review will focus on recent research and theories seeking to establish causation for disease and offer treatment recommendations. Keywords: Endometriosis; Environmental toxins; Xenoestrogens;
    [Show full text]